Novartis Ag

Glaxosmithkline Biologicals Sa

J. Craig Venter Institute

Novartis Vaccines & Diagnostics, Gmbh

Novartis Vaccines and Diagnostics Srl

Ospedale San Raffaele S.r.l.

Chiron S.r.l.

Novartis Ac

J. Craig Venture Institute, Inc.

Chrion S.r.l.

Vega Masignani

Maria Scarselli

Mariagrazia Pizza

Guido Grandi

Rino Rappuoli

Herve Tettelin

Marirosa Mora

Cesira Galeotti

Vincenzo Scarlato

Claire M Fraser

John Telford

Erin Hickey

Giulio Ratti

Jeremy Petersen

J Craig Venter

Marzia Monica Giuliani

Maurizio Comanducci

Maria Rita Fontana

Nathalie Norais

Laura Serino

Danilo Gomes Moriel

Maria Arico

Francesco Berlanda Scorza

Susan Barnett

Indresh K Srivastava

Fabio Bagnoli

Barbara Capecchi

Beatrice Maria Arico

Guilio Ratti

Matthew Bottomley

Victoria A Sharma

Maria Aricò

Mariarosa Mora

Marizia Monica Guiliani

Michele Anne Barocchi

Roberto Petracca

Elisabetta Monaci

Brunella Brunelli

Hervé Tettelin

Craig Venter

Maria Beatrice Arico

Daniele Veggi

Monica Moschioni

Paolo Ruggiero

Claudio Donati

Marzia Monica Guiliani

Irene Bianconi

Maria Rosa Mora

Alessandra Bragonzi

Giulo Ratti

Jeremy D Peterson

Beatriz Alcala′ Franco

Craig Ventor

Alessia Biolchi

Beatriz Alcala' Franco

Alessandro Muzzi

Michéle Barrochi

Mariagratia Pizza

Enzo Scalato

Laura Ciucchi

Federica Di Marcello

Maria B Arico

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.

Modified meningococcal fHbp polypeptides

Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.

Meningococcus vaccines

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.

The invention provides proteins from group B() and group A(), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins from streptococcus groups A and B

The invention provides proteins fromincluding amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.

[object Object]

Disclosed herein are various open reading frames from a strain ofresponsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

An effectivevaccine may require one or several antigenic components, and so various antigens ofare identified for use in immunization. These polypeptides may optionally be used in combination with other nosocomial antigens.

Two or more Neisserial proteins (e.g. A and B) are expressed as a single hybrid protein which can be represented simply by the formula NH-A-B&#x2014;COOH.

Hybrid expression of neisserial proteins

The invention provides proteins from, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Growing community of inventors

Siena, Italy

Vega Masignani